phenylalanine has been researched along with Cardiovascular Diseases in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (29.63) | 29.6817 |
| 2010's | 15 (55.56) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Jia, W; Jiao, J; Liu, X; Wan, X; Wang, A; Wang, Q; Zhang, L; Zhang, Y; Zhu, L; Zhuang, P | 1 |
| Han, L; Sun, H; Sun, J; Wang, Y; Xu, D; Xu, Y; Zhang, B | 1 |
| Abu-Remaileh, M; Benson, MD; Chen, ZZ; Cruz, DE; Deng, S; Dong, W; Gerszten, RE; Guo, Y; Li, VL; Long, JZ; Lyu, X; Moya-Garzon, MD; Shi, X; Sims, M; Tahir, UA; Tanzo, JT; Wei, W; Wiggenhorn, AL; Wilson, JG; Zheng, S | 1 |
| Baykan, A; Kardaş, F; Kendirci, M; Yılmaz, BK | 1 |
| Bethel, MA; Califf, RM; Charbonnel, B; Diem, P; Haffner, SM; Holman, R; Horton, ES; Krum, H; Leiter, LA; Mareev, V; McMurray, JJ; Reyes, EM; Schaper, F; Shah, BR; Shen, L; Soska, V; Sun, JL; Thomas, L; Wojdyla, D | 1 |
| Califf, RM; Katz, M; Lopes, RD; McMurray, JJ; Sun, JL; Thomas, L | 1 |
| Adamski, J; Ala-Korpela, M; Artati, A; Casas, JP; Chaturvedi, N; Gaunt, TR; Gerszten, RE; Ghorbani, A; Havulinna, AS; Hughes, AD; Illig, T; Jula, A; Kähönen, M; Kaikkonen, J; Kangas, AJ; Kettunen, J; Lawlor, DA; Lehtimäki, T; Mikkilä, V; Perola, M; Prieto-Merino, D; Raitakari, OT; Ripatti, S; Salomaa, V; Sattar, N; Soininen, P; Tiainen, M; Tillin, T; Tynkkynen, T; Vasan, RS; Wang, Q; Wang, TJ; Würtz, P | 1 |
| Bales, CW; Bethel, MA; Califf, RM; Davies, MJ; Haffner, SM; Holman, RR; Huffman, KM; Kraus, WE; McMurray, JJ; Preiss, D; Schulte, PJ; Thomas, L; Tuomilehto, J; Yates, T | 1 |
| Banderali, G; Cefalo, G; Giovannini, M; Lassandro, C; Moretti, F; Radaelli, G; Salvatici, E; Verduci, E | 1 |
| Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP | 1 |
| Harumi Higuchi Dos Santos, M; Holman, RR; Lopes, RD; McMurray, JJ; Pieper, K; Sharma, A; Sun, JL | 1 |
| Bethel, MA; Califf, RM; Gerlock, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Krum, H; McMurray, JJ; Zuurman, L | 1 |
| Nathan, DM | 1 |
| Belenkov, Y; Bethel, MA; Boolell, M; Buckley, BM; Buse, JB; Califf, RM; Chacra, AR; Charbonnel, B; Chiang, FT; Chow, CC; Davies, MJ; Deedwania, P; Diem, P; Einhorn, D; Fonseca, V; Fulcher, GR; Gaciong, Z; Gaztambide, S; Giles, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Hua, TA; Ilkova, H; Jenssen, T; Kahn, SE; Krum, H; Laakso, M; Leiter, LA; Levitt, NS; Mareev, V; Martinez, F; Masson, C; Mazzone, T; McMurray, JJ; Meaney, E; Nesto, R; Pan, C; Prager, R; Raptis, SA; Rutten, GE; Sandstroem, H; Schaper, F; Scheen, A; Schmitz, O; Sinay, I; Soska, V; Stender, S; Tamás, G; Tognoni, G; Tuomilehto, J; Villamil, AS; Vozár, J | 2 |
| Scheen, AJ | 1 |
| Bellomo Damato, A; Giorgino, F; Giorgino, R; Laviola, L; Stefanelli, G | 1 |
| Abdelmoneim, AS; Brocks, DR; Hasenbank, SE; Light, PE; Seubert, JM; Simpson, SH | 1 |
| Bodamer, OA; Huemer, M; Mayr, D; Möslinger, D; Mühl, A; Schmid, I; Simma, B; Ulmer, H | 1 |
| Odawara, M | 1 |
| Ishida, H; Kadowaki, T; Kawamori, R | 1 |
| Hirose, T | 1 |
| Tsujii, S | 1 |
| Anastasopoulou, I; Boutati, E; Karafoullidou, A; Karambakalis, N; Katsilambros, N; Kyriaki, D; Lourida, E; Perea, D; Perrea, D; Raptis, SA; Tentolouris, N; Tselepis, AD; Tsoukala, C | 1 |
| Aloisi, F; Cappelli, V; De Cian, F; Di Martino, M; Gandolfo, MT; Garibotto, G; Procopio, V; Sala, MR; Sofia, A; Tarroni, A; Verzola, D; Villaggio, B | 1 |
| Arakawa, M; Hirose, T | 1 |
| Yudkin, JS | 1 |
7 review(s) available for phenylalanine and Cardiovascular Diseases
| Article | Year |
|---|---|
Diet in children with phenylketonuria and risk of cardiovascular disease: A narrative overview.
Topics: Adiponectin; Arginine; Blood Pressure; Cardiovascular Diseases; Child; Cholesterol, HDL; Cholesterol, LDL; Diet; Homocysteine; Humans; Oxidative Stress; Pediatric Obesity; Phenylalanine; Phenylketonurias; Risk Factors | 2016 |
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Topics: Adult; Benzamides; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Fasting; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Middle Aged; Nateglinide; Phenylalanine; Randomized Controlled Trials as Topic; Sulfonylurea Compounds | 2016 |
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohexanes; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Ischemic Preconditioning, Myocardial; Isoindoles; Mice; Muscle, Smooth, Vascular; Myocytes, Cardiac; Nateglinide; Phenylalanine; Piperidines; Potassium Channels, Inwardly Rectifying; Rats; Receptors, Drug; Risk Factors; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |
[Nateglinide and mitiglinide].
Topics: Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Indoles; Insulin; Insulin Resistance; Insulin Secretion; Isoindoles; Metformin; Nateglinide; Phenylalanine; Postprandial Period; Stimulation, Chemical | 2003 |
[Effects of nateglinide in impaired glucose tolerance subjects].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Nateglinide; Obesity; Phenylalanine; Postprandial Period; Risk Factors | 2005 |
[NAVIGATOR trial (nateglinide)].
Topics: Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Endpoint Determination; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Life Style; Nateglinide; Phenylalanine; Primary Prevention; Randomized Controlled Trials as Topic; Risk | 2005 |
[Glinide(s), sulfonylurea(s)].
Topics: Arteriosclerosis; Cardiovascular Diseases; Cyclohexanes; Diabetic Angiopathies; Glucose Intolerance; Hyperglycemia; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Isoindoles; Nateglinide; Phenylalanine; Postprandial Period; Risk Factors; Sulfonylurea Compounds | 2006 |
8 trial(s) available for phenylalanine and Cardiovascular Diseases
| Article | Year |
|---|---|
Metabolomics strategy comprehensively unveils the effect of catechins intervention on the biomarkers of exposure to acrylamide and biomarkers of cardiometabolic risk.
Topics: Acrylamide; Adult; Alanine; Animals; Antioxidants; Aspartic Acid; Biomarkers; Capsules; Cardiovascular Diseases; Catechin; Citric Acid; Glutamic Acid; Glutamine; Glycolipids; Humans; Ketoglutaric Acids; Metabolomics; Phenylalanine; Polyphenols; Rats; Tea | 2022 |
Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Confidence Intervals; Cyclohexanes; Female; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Prevalence; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan; Venous Thromboembolism | 2015 |
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patient Selection; Phenylalanine; Prediabetic State; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Treatment Failure; Valine; Valsartan | 2010 |
Effect of valsartan on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
[NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].
Topics: Angiotensin II Type 1 Receptor Blockers; Belgium; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2011 |
Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Topics: Adult; Aged; Blood Coagulation; Cardiovascular Diseases; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Humans; Hypoglycemic Agents; Lipids; Male; Metabolism; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome | 2005 |
12 other study(ies) available for phenylalanine and Cardiovascular Diseases
| Article | Year |
|---|---|
Higher dietary intake of aromatic amino acids was associated with lower risk of cardiovascular disease mortality in adult participants in NHANES III.
Topics: Adult; Amino Acids; Amino Acids, Aromatic; Cardiovascular Diseases; Cohort Studies; Eating; Humans; Nutrition Surveys; Phenylalanine; Tryptophan; Tyrosine; United States | 2023 |
CYP4F2 is a human-specific determinant of circulating N-acyl amino acid levels.
Topics: Amino Acids; Cardiovascular Diseases; Cytochrome P450 Family 4; Fatty Acids; Humans; Leucine; Oleic Acids; Phenylalanine | 2023 |
Evaluation of the effect of obesity, dietary glycemic index and metabolic profiles on the cardiovascular risk in children with classical phenylketonuria.
Topics: Cardiovascular Diseases; Child; Cholesterol; Glucose; Glycemic Index; Heart Disease Risk Factors; Humans; Metabolome; Obesity; Phenylalanine; Phenylketonurias; Prospective Studies; Pulse Wave Analysis; Risk Factors | 2023 |
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Models, Statistical; Nateglinide; Phenylalanine; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts.
Topics: Adolescent; Adult; Age Distribution; Aged; Biomarkers; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Child; Comorbidity; Diabetes Mellitus; Docosahexaenoic Acids; Endophenotypes; Fatty Acids, Monounsaturated; Fatty Acids, Omega-6; Female; Finland; Health Surveys; High-Throughput Screening Assays; Humans; Male; Mass Spectrometry; Metabolomics; Middle Aged; Nuclear Magnetic Resonance, Biomolecular; Phenylalanine; Prospective Studies; Risk Assessment; Risk Factors; Sex Distribution; Smoking; United Kingdom; United States; Young Adult | 2015 |
Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial.
Topics: Accelerometry; Actigraphy; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cohort Studies; Cyclohexanes; Fasting; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Middle Aged; Motor Activity; Nateglinide; Phenylalanine; Prospective Studies; Regression Analysis; Risk Factors; Risk Reduction Behavior; Valsartan | 2015 |
International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asia; Australia; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Europe; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Latin America; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Nateglinide; New Zealand; North America; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; South Africa; Stroke; Valsartan | 2017 |
Navigating the choices for diabetes prevention.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Tetrazoles; Valine; Valsartan | 2010 |
Free asymmetric dimethylarginine (ADMA) is low in children and adolescents with classical phenylketonuria (PKU).
Topics: Adolescent; Arginine; Atherosclerosis; Blood Glucose; Cardiovascular Diseases; Child; Cross-Sectional Studies; Female; Homocysteine; Humans; Lipid Metabolism; Male; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Phenylalanine; Phenylketonurias | 2012 |
[Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].
Topics: Administration, Oral; Cardiovascular Diseases; Cyclohexanes; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Indoles; Inositol; Insulin; Insulin Resistance; Insulin Secretion; Isoindoles; Nateglinide; Phenylalanine; Risk Factors; Stimulation, Chemical; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Peripheral tissue release of interleukin-6 in patients with chronic kidney diseases: effects of end-stage renal disease and microinflammatory state.
Topics: Aged; Arteries; Biopsy; Cardiovascular Diseases; Female; Forearm; Gene Expression; Humans; Immunohistochemistry; Inflammation; Interleukin-1; Interleukin-10; Interleukin-6; Male; Middle Aged; Muscle, Skeletal; Phenylalanine; Renal Insufficiency, Chronic; RNA, Messenger; Tumor Necrosis Factor-alpha; Uremia; Veins | 2006 |
Post-load hyperglycaemia-an inappropriate therapeutic target.
Topics: Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Patient Selection; Phenylalanine; Postprandial Period; Practice Guidelines as Topic; Predictive Value of Tests | 2002 |